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Abstract
Stable integration of HIV proviral DNA into host cell chromosomes, a hallmark and essential feature of the retroviral life
cycle, establishes the infection permanently. Current antiretroviral combination drug therapy cannot cure HIV infection.
However, expressing an engineered HIV-1 long terminal repeat (LTR) site-specific recombinase (Tre), shown to excise
integrated proviral DNA in vitro, may provide a novel and highly promising antiviral strategy. We report here the conditional
expression of Tre-recombinase from an advanced lentiviral self-inactivation (SIN) vector in HIV-infected cells. We
demonstrate faithful transgene expression, resulting in accurate provirus excision in the absence of cytopathic effects.
Moreover, pronounced Tre-mediated antiviral effects are demonstrated in vivo, particularly in humanized Rag22/2cc2/2
mice engrafted with either Tre-transduced primary CD4+ T cells, or Tre-transduced CD34+ hematopoietic stem and
progenitor cells (HSC). Taken together, our data support the use of Tre-recombinase in novel therapy strategies aiming to
provide a cure for HIV.
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) into clinical practice in the mid-1990s profoundly
reduced morbidity and mortality among HIV-1-infected patients,
changing an almost always fatal disease into a manageable chronic
illness [1]. However, HAART is costly and occasionally not well
tolerated [2,3]. Particularly long-term HAART is frequently
accompanied by emerging new toxicities, resulting in secondary
complications that include metabolic disorders (e.g. diabetes,
hyperlipidemia), osteoporosis, cardiovascular disease and chronic
kidney disease (reviewed in [4–6]). Furthermore, large cohort
studies demonstrated that the life expectancy of patients receiving
HAART still remains considerably shorter than that of uninfected
subjects (recently reviewed in [7]). Most importantly, the fact that
HAART does not eradicate HIV and that treatment intensifica-
tion, even when employing advanced drug regimens, fails to
completely clear the virus (reviewed in [7,8]) highlights the
urgency of pursuing new strategies to find a cure for HIV
infection.
It is generally believed that the main hurdle to virus eradication
is the persisting HIV-1 infection in latent reservoirs, particularly in
memory CD4+ T cells (reviewed in [9–15]). Latently HIV-1-
infected resting CD4+ T cells are apparently established early in
infection. One current strategy to eliminate this pool of long-lived
cells aims to specifically activate the transcriptionally quiescent
provirus (i.e. the integrated replication-competent HIV-1 genome),
for example by modifying its chromatin structure through histone
deacetylase (HDAC) inhibitors (reviewed in [12,13,15–17]). Upon
HDAC inhibitor-induced HIV-1 antigen expression, it is expected
that these cells either experience HIV-1-induced cell death or are
eliminated by cytotoxic T cells (CTLs). It is fair to assume that
such purging strategies would greatly benefit from a technology
that can concurrently remove integrated HIV-1 from the pool of
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productively infected cells, thereby restoring, or at least improving
the patient’s immune function.
A novel strategy to remove integrated HIV-1 is based on a
tailored site-specific recombinase (Tre), derived by molecular
evolution of the bacteriophage recombinase Cre [18–20]. Tre
targets a specific 34 bp sequence (loxLTR) derived from a primary
HIV-1 strain [21] located in the proviral LTR regions, resulting in
excision of the integrated proviral DNA from the genome of
infected cultured cells [18]. This process not only suppresses viral
replication, but in theory may also help eradicate HIV from an
infected individual (reviewed in [22]).
Administering Tre-recombinase to patients will most likely
require a gene therapy approach. In principle, genetic therapies
against HIV either modify the patient’s peripheral CD4+ T cells or
patient-derived CD34+ hematopoietic stem cells (HSC) [23–25]. It
is anticipated that the former strategy would lead to beneficial
antiviral, although transient effects. The latter application will
presumably be the preferred strategy in Tre-based virus eradica-
tion approaches, since, in theory, it allows perpetual repopulation
of the patient’s hematopoietic system with Tre-expressing HIV-1
target cells. These cells may be selected in vivo [26], since upon de
novo infection they are able to remove the integrated HIV-1
proviral DNA, and thus remain functionally immune competent.
Independently of the selected gene therapy strategy, and prior
to its potential use in HIV-infected patients, vector technology has
to be developed that allows safe and efficient gene transfer
followed by reliable transgene expression in target cells. Moreover,
the absence of cytopathic and/or genotoxic effects upon vector-
mediated Tre expression, and the accurate excision of HIV
proviral DNA from chromosomal integration sites has to be
demonstrated. Finally, the antiviral effects of Tre-recombinase
have to be shown in vivo, i.e. in an appropriate animal model for
HIV-1 infection. All these analyses will be of utmost importance
for developing a potential Tre-based therapy to treat HIV
infection.
Results
Conditional lentiviral vector-mediated Tre delivery
For delivery of Tre-recombinase an HIV-1-derived replication-
incompetent lentiviral vector (LV) was constructed that provides
high safety levels due to a split packaging system; the self-
inactivating (SIN) vector design; and a sequence element
introduced to improve transcriptional termination [27,28]
(Figure 1A). To avoid transgene-related side effects, the gene
sequence encoding Tre-recombinase was placed under the control
of an engineered Tre-resistant tandem TAR repeat (2TAR), the
cis-active target sequence of the HIV-1 Tat trans-activator [29].
This not only limits Tre expression to HIV-infected cells, but a
duplicated TAR element also positively influences internal LTR
promoter activity in the presence of Tat (Figure S1 in Text S1).
Finally, constitutive expression of the GFP marker protein was
facilitated by the PGK promoter (Figure 1A).
First, we investigated whether Tre-recombinase introduced by
the LV construct is faithfully expressed in HIV-infected cells, and
in turn, excises integrated chromosomal proviral DNA. We
generated a reporter cell line, HeLa-smurf, which is stably infected
with a replication-incompetent HIV-1 mutant with the env gene
partially deleted and the nef open reading frame partially replaced
by a marker gene (blb) (Figure 1B). Thus, Tre-mediated excision of
the proviral genome results in loss of blue fluorescent protein (BFP)
expression, which can be tracked by flow cytometry.
To monitor Tre activity, HeLa-smurf cells were transduced in
triplicates with the GFP-expressing LV particles LV-Tre or a
scrambled tre version, the Tre-negative control construct LV-Ctr,
cultured for various time periods and analyzed for BFP and GFP
expression. After transduction, both lentiviral constructs produced
a GFP/BFP double positive cell population (see top right
quadrants in Figure 1C, and plotted data in Figure S2 in Text
S1). However, whereas the BFP/GFP double positive population
of LV-Ctr-transduced cells subsequently remained stable over
time, the BFP/GFP double positive population observed in LV-
Tre treated cells started to decrease at 72 hours post transduction
(Figure 1C and Figure S2 in Text S1). Simultaneously, the GFP-
only positive population increased, suggesting that Tre-mediated
excision of HIV-1 proviral DNA has occurred. Importantly, as the
BFP/GFP double-positive population declined, expression of Tre-
recombinase decreased, owing to the Tat-driven promoter
providing temporal Tre expression (Figure 1D).
We performed a panel of assays to verify Tre-mediated excision
of the provirus. First, we investigated the excised circular
recombination product using a PCR assay (Figure 2A). An
excision-specific fragment was only detected in DNA prepared
from Tre-treated HeLa-smurf cells (LV-Tre), but not in cells
treated with the negative control vector (LV-Ctr) (Figure 2B). The
recombination product appeared as early as 24 hours after
transduction, and can be detected until 6 days post transduction
(p.t.) time point. As expected, the intensity of the PCR signal
continuously increased, reaching a maximum at day 4 p.t., before
starting to decline (Figure 2B). The direct sequencing of the LTR
and its flanking regions confirmed that Tre-mediated recombina-
tion of loxLTR sequences had occurred in a highly accurate
fashion, exactly maintaining the 34 bp loxLTR Tre-specific target
sequence (Figure 2D). Importantly, the time-based occurrence and
intensity of the excised proviral DNA closely corresponded with
the declining BFP signal (Figure 1C and Figure S2 in Text S1),
and coincided with temporal Tre expression (Figure 1D). Second,
we only detected the remaining single LTR (i.e. genomic scar) in
Tre-treated cells by PCR [30] (Figure 2C). Third, we identified a
total of three proviral integration sites in genomic DNA from
transduced HeLa-smurf cells by nrLAM PCR and high through-
put sequencing [31] (Table S1 and Figure S3–Figure S5 in Text
S1). As expected, proviral coding sequences (LTR/blb), as opposed
to genomic sequences (LTR/int), were under-represented in Tre-
treated cells compared to HeLa-smurf cells treated with the
control vector as shown for one specific integration site by
Author Summary
Current antiretroviral combination therapy can efficiently
suppress virus replication, but cannot eliminate HIV.
Therefore, no cure for HIV exists. A main hurdle for virus
eradication is seen in the existence of resting cells that
contain integrated replication-competent, but temporarily
silenced, HIV genomes. Therefore, the most direct ap-
proach to eliminating virus reservoirs is to remove HIV
genomes from infected cells. As previous studies suggest-
ed, this may be achievable by Tre-recombinase, an
engineered enzyme that can excise integrated HIV from
host cell chromosomes. The present work analyzes the
expression of Tre-recombinase in human cells and dem-
onstrates highly accurate Tre activity in complete absence
of Tre-related cytopathic effects. Furthermore, in vivo
analysis of Tre-recombinase demonstrates highly signifi-
cant antiviral effects of Tre in HIV-infected humanized
mice. The presented data suggest that Tre-recombinase
might become a valuable component of a future therapy
that aims at virus eradication.
HIV-1 Excision by LTR-Specific Recombinase In Vivo
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quantitative PCR (Figure 2E–G) as well as by integration site-
independent next generation sequencing (Table 1). Thus, LV-Tre
represents an efficient HIV-1 specific expression system for
excising integrated HIV-1 provirus from cells.
Absence of Tre-related cytotoxicity
The expression of antiviral genes may induce undesired effects,
which could compromise host cell function. To analyze potential
Tre-related cytotoxicities, Tre was overexpressed for a period of
15 weeks in Jurkat T cells; i.e. using the constructs LV-cTre and
LV-cCtr in which the 2TAR promoter was replaced by the
cellular EF1a promoter, permitting constitutive transgene (Tre)
expression. Analyses of cellular metabolic activity (measured by an
MTT assay), cell cycle progression (determined by DNA staining
with propidium iodide) and apoptosis (assayed by Annexin V
staining) did not reveal any deleterious effect of Tre expression on
the host cells (Figure 3A–3D, respectively). This was also reflected
by comparable cellular growth curves, independently of whether
Tre-recombinase was expressed (Figure S6 in Text S1).
We also investigated possible effects of Tre expression on
hematopoiesis and immune function. We transduced primary
human CD4+ T lymphocytes with LV constitutively overexpress-
ing the GFP marker protein and either Tre or the negative control.
Subsequently, the GFP-positive cells (,90% of the cultures) were
analyzed with respect to immune activation by FACS, multiplex
cytokine-ELISA and IL4 and IFNc Elispot assays (Figure 3E–3G,
Figure 1. Tre-mediated antiviral activity by conditional transgene expression. (A) The HIV-derived lentiviral vector (LV) contains self-
inactivating (SIN) long terminal repeats (LTR: DU3, R, U5), a Rev response element (RRE), central polypurine tract (cPPT), transgene cassette, post-
regulatory element derived from woodchuck hepatitis virus (PRE), SV40 upstream polyadenylation enhancer elements (USE), splice donor (SD), splice
acceptor (SA), and packaging (Y) signal, and the open reading frame for Tre-recombinase (tre) under the control of an HIV-LTR promoter containing
two TAR elements (2TAR). In addition, the LV-Tre construct encodes the open reading frame for enhanced GFP (egfp). Expression of egfp is facilitated
by the PGK promoter (PGK). (B) Schematic diagram of the replication–incompetent proviral reporter construct pNLT2DenvBLB. The open reading
frame for the BFP-blasticidin-S deaminase fusion protein (blb) (blue box) partially substitutes the nef coding region. The 59 and 39 LTRs contain the Tre
recombination site (loxLTR), a native HIV sequence. (C) Flow cytometric analysis of propidium iodide negative cells from one representative infection
experiment follows the progression of GFP and BFP expression in polyclonal HeLa-smurf cells transduced with the indicated lentiviral constructs. (D)
Tre and GFP expression was visualized by Western blot analysis. GAPDH served as a loading control.
doi:10.1371/journal.ppat.1003587.g001
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respectively). These analyses suggest that prolonged overexpres-
sion of Tre does not negatively affect cellular activation of primary
lymphocytes. We furthermore investigated the capacity of Tre
vector-transduced CD34+ HSC to differentiate into various
hematopoietic lineages using colony forming unit (CFU) assays.
In all experiments, Tre vector-transduced HSC maintained their
capacity to differentiate into the expected lineages (Figure 3H and
3I), with no significant differences from the controls.
For further analyses, Tre was constitutively overexpressed for 21
days in primary human CD4+ T cells and potential chromosomal
alterations were subsequently analyzed by spectral karyotyping
(SKY) [32] and array-comparative genomic hybridization (array-
CGH) [33]. The combination of these cytogenetic assays exhibited
neither chromosomal translocations, nor variations in DNA copy-
number changes (Figure 4A and 4B and Figure S7 in Text S1).
Thus, Tre appears to lack any obvious off-target activity in human
cells, at least within the limitations of these experimental systems.
Next we investigated other potential undesired alterations due
to Tre expression. A recent transcriptome analysis using whole
human genome microarrays found no differences between Tre-
treated and untreated control cells [34], indicating that the
expression of Tre does not alter the expression profile of cells. To
Figure 2. Tre-mediated provirus excision and determination of Tre efficacy. (A) Schematic depiction of Tre-mediated recombination. The
PCR primers P1 and P2 amplify sequences from the provirus into the LTRs. Site-specific Tre-mediated recombination leaves a single LTR in the
genome (‘‘genomic scar’’) and excises a circular recombination product containing the P1 and P2 primer binding regions. (B) Genomic DNA isolated
from HeLa-smurf cells transduced with LV-Tre or LV-Ctr was analyzed by PCR using the P1 and P2 primers to detect the circular recombination
product (1 kb). Negative PCR control, mock; lane M: DNA marker; p.t., post transduction. (C) To detect the genomic scar, genomic DNA prepared from
Tre-treated (Tre +) or Ctr-treated cells (Tre 2) 3 days after transduction were used as templates for PCR using HiLo PCR. Negative PCR control, mock;
lane M: DNA marker. (D) The LTR region in the circular recombination product was subjected to DNA sequencing, revealing the presence of a single
LTR flanked by nef-derived and gag leader sequences. Tre-treatment resulted in precise loxLTR recombination (boxed). (E) Genomic DNA containing
either a single full length proviral genome or the residual LTR (‘‘genomic scar’’) is subjected to nrLAM PCR using LTR-specific primers (LTRIII).
Subsequently, LAM PCR products consisting of LTR and genomic host DNA (LTR/int; 146 bp) or LTR and proviral coding sequence (LTR/blb; 150 bp)
were quantified by qPCR. (F) Semi-quantitative PCR analysis of LAM PCR products from Tre-treated cells (Tre +), Ctr-treated control cells (Tre 2) or
negative PCR control (Ø). Lane M: DNA marker. (G) Quantitative PCR determination of LTR/int and LTR/blb LAM PCR products from Tre-treated cells
(Tre +) or Ctr-treated (Tre 2) control cells. Given are the means of three independent PCR reactions.
doi:10.1371/journal.ppat.1003587.g002
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verify Tre’s target specificity, the SeLOX algorithm [35], a locus
of recombination site search tool, was employed to scan the
human genome for potential Tre target sites. Seven independent
sequences that occur in the human genome and display the highest
sequence similarity to loxLTR (5–8 nucleotide mismatches in the
specificity-determining loxLTR halfsites) were tested as sites for
Tre-mediated recombination in E. coli and HeLa cells (Figure 5).
No recombination (above background signal) was detectable after
strong and prolonged expression of Tre in E. coli or HeLa,
respectively, demonstrating that naturally occurring human
loxLTR-like sites are not a substrate for the recombinase.
However, by screening the Los Alamos HIV sequence database
(http://www.hiv.lanl.gov/), two additional independent clinical
HIV-1 isolates were identified with subtle single nucleotide
loxLTR variations that served as Tre targets (Method S1 and
Figure S8 in Text S1). These findings suggest that Tre does not
alter or recombine human chromosomal sequences (Figure 4 and
Figure 5) but may recognize certain s\ingle nucleotide alterations
in the loxLTR site of a variety of clinical HIV-1 isolates.
In conclusion, the combined data indicate that LV-mediated
expression of Tre-recombinase does not induce cytopathic effects
in human hematolymphoid cells.
Tre-mediated antiviral activity in humanized mice
Two approaches, suggested as gene therapies against HIV
[23,24], were taken to test the ability of Tre to suppress HIV-1
infection in vivo. In the first approach, human CD4+ T cells were
isolated from buffy-coats and transduced with LV-Tre or LV-Ctr
particles, routinely resulting in ,60% GFP+ cells (as measured by
FACS; not shown). Then 6-week-old Rag22/2cc2/2 mice were
conditioned with clodronate, irradiated and transplanted with
36106 cells of the transduced total cell pools, which were
characterized by CCR5 surface expression (Figure S9 in Text
S1). Rag22/2cc2/2 animals lack B, T, and NK cells, can be
engrafted with either CD4+ T cells or CD34+ HSC, and in both
cases, support HIV-1 infection [36–39].
The engraftment of human lymphocytes was verified at 8 to 10
weeks post transplantation by FACS analysis of PBMCs,
determining the percentage of mouse CD45+, human CD45+,
human CD4+, and GFP+ cells. To assess Tre activity, mice with
$1% human CD45+CD4+GFP+ peripheral cells were then
infected by intra-peritoneal injection of 100 ng p24 antigen of
the replication-competent CCR5-tropic HIV-1 pNLT2env(-
BaL)mcherry, bearing loxLTR sites derived from the primary
HIV-1 isolate TZB0003 [21]. Since we wanted to monitor Tre-
mediated antiviral effects as directly as possible, i.e. by analyzing
plasma viremia, this challenge virus does intentionally not encode
a functional Nef protein. It is known that intact Nef depletes CD4+
T cells in humanized mouse models, thereby also indirectly
affecting viral loads [40,41]. Therefore, Nef-mediated pathogenic
effects were not addressed in the following in vivo analyses.
Upon infection, viral loads, GFP+ cells and PBMC surface
markers (see Materials and Methods section) were subsequently
monitored over time. Inspection of the data obtained from the
individual animals revealed suppression of HIV-1 viremia in the
plasma of the mice transplanted with Tre-transduced cells (LV-
Tre; animal T1–11), but not in the negative control animals (LV-
Ctr; animal T12–18; Figure 6). Moreover, in contrast to LV-Ctr
treated animals, the percentage of human CD45+CD4+ cells
increased during the 16 week observation period in the mice that
received Tre-transduced CD4+ T cells (Figure 6). It should be
noted that the engraftment of immune deficient mice with human
cells is to a significant extent donor dependent, a fact that impacts
on the animals’ infection rates. Therefore, to obtain statistics, the
HIV-1 RNA copies in the mice at week 2 post infection were set to
100% and the fold difference of the change in these baseline levels
was followed over time. This analysis revealed a highly significant
reduction of the viral load (p =,0.0001, n= 11; for statistical
method see Materials and Methods section) in mice transplanted
with Tre-transduced cells, as opposed to animals that received cells
transduced with the negative control vector (p = 0.0811, n= 7)
(Figure 7A). Moreover, the increase in the percentage of human
CD45+CD4+ cells, particularly in Tre-treated mice as opposed to
control animals was clearly significant (Figure 7B). This trend was
also seen when assessing the percentage of CD4+GFP+ cells
(Figure 7C). At 16 weeks after infection, animals were euthanized
and various tissues analyzed. Immunohistochemistry on spleen
sections clearly revealed reduced numbers of HIV-infected cells in
a Tre-treated as compared to a control animal (Figure 7D). FACS
analyses of single cell suspensions derived from bone marrow,
liver, spleen and thymus showed an enrichment of CD4+GFP+
cells, particularly in animals that had received Tre-transduced cells
(Figure S10 in Text S1).
In a second in vivo approach to study Tre-based antiviral effects,
newborn Rag22/2cc2/2 mice were irradiated and transplanted
by intrahepatic injection with 36105 LV-Tre and LV-Ctr
transduced human CD34+ HSC. The transduction rate of these
cord blood-derived hematopoietic cells typically resulted in ,30%
GFP+ cells (not shown). Engraftment was verified at 10 to 12 weeks
post transplantation by FACS analysis of PBMCs (determining the
percentage of mouse CD45+, human CD45+, human CD19+,
human CD3+, human CD4+ and GFP+ cells). Generally, animals
with $0.5% of CD45+CD4+GFP+ lymphocytes in their peripheral
blood were challenged with HIV-1 as described above. As shown,
in all LV-Tre treated animals (HSC1–10), as opposed to mice that
received LV-Ctr transduced HSC (HSC11–18), the individual
viral load declined over time and the percentage of human
CD45+CD4+ cells either increased or remained constant (Figure 8).
Subsequent statistical analysis at week 12 post infection revealed
that mean viremia in mice that received LV-Tre transduced HSC
was significantly diminished (p=,0.0001, n= 10) compared to
control (i.e. LV-Ctr) animals (p = 0.5377, n = 8) (Figure 9A),
indicating a progressive loss of viral loads in Tre-treated animals
over time. In contrast to the human CD4+ T cell transplanted
animals, the percentage of CD45+CD4+ T cells did not change
significantly in these mice (Figure 9B). This may be explained by
the fact that only a fraction of the transplanted HSC (,30%) were
Tre-transduced, and thus protected from HIV replication.
CD4+GFP+ cells were detected over the entire 12-week period,
demonstrating the successful development of LV-transduced
peripheral T cells in these HSC transplanted mice (Figure 9C).
The immunohistochemical analysis of human CD3+ and HIV-1
p24 antigen expressing cells in lymph nodes of representative
Table 1. High throughput sequencing of nrLAM-PCR
products.
LV - Ctr LV - Tre
total # of mapped readsA 4445 1009
proviral coding regionB 1140 (25.6%) 165 (16.4%)
integration siteC 3305 (74.4%) 844 (83.6%)
Anumber of quality-filtered reads that could be mapped to genomic or viral
sequences (see Materials and Methods for details).
B,Cnumber and percentages of reads mapping B to flanking/integration site
specific sequences, or C to Nef-encoding proviral sequences.
doi:10.1371/journal.ppat.1003587.t001
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euthanized mice demonstrated that p24+ cells were distinctly
depleted in mice that received LV-Tre transduced HSC
(Figure 9D). Furthermore, FACS analysis of cell suspensions
derived from bone marrow or spleen of these mice verified the
presence of transgenic human cells representing various hemato-
poietic lineages, including CD4+ and CD8+ T lymphocytes, pre-B
and activated B cells, cells committed to the monocyte/macro-
phage lineage, NK cells and NKT cells (see Figure S11 in Text
S1).
Collectively, the in vivo experiments document the antiviral
activity of Tre-recombinase at the organismal level.
Discussion
The clinical development of HAART has been one of the great
successes in modern medicine. However, the fact that HAART
cannot eradicate HIV [7,8] makes investigating novel antiviral
strategies a prerequisite for developing a future cure for HIV
infection [7,9,12]. In effect, gene therapy strategies represent a
technology holding high promise for future antiviral disease
treatments [22–25]. Indeed, various RNA-based technologies are
currently being investigated in vivo, including, for example, the
expression of RNA aptamers, siRNAs and shRNAs, TAR decoys,
and ribozymes [42–44]. Moreover, the expression of membrane-
bound fusion inhibitors is another appealing antiviral strategy
[45,46]. These approaches efficiently suppress virus replication,
and thus reduce viral loads for extended periods of time. Another
promising strategy appears to be disruption of the CCR5 gene
[47,48], for example by expressing engineered zinc finger
nucleases (ZFN) [20]. In humanized mice transplanted with either
CD4+ T cells or CD34+ HSC, ZFN-mediated CCR5 disruption
has been shown to confer resistance to de novo infection by CCR5-
tropic HIV-1, thereby controlling virus replication [49,50].
In contrast, an antiviral strategy based on Tre-recombinase is
independent of virus coreceptor usage (i.e. tropism) and can target
cells that are already infected with HIV [18,34]. Importantly, Tre-
mediated provirus excision allows reversal of HIV infection at the
cellular level, thereby avoiding viral cytopathic effects (e.g. effects
associated with viral antigen expression) and possibly restoring
host cell function. As shown here, Tre expression mediated highly
significant antiviral effects, which were equally observed in animals
engrafted with Tre-expressing CD4+ T cells or Tre-expressing
CD34+ HSC. With respect to future clinical studies, this Tre effect
is particularly impressive, since the animals had been transplanted
with unselected cell pools, where only a fraction of the T cells
(,60%) or the HSC (,30%) harbored the Tre expressing
lentiviral vector. Apparently, Tre-mediated protection of only a
subpopulation of HIV-1 target cells suffices to achieve significant
antiviral effects in vivo. This may be explained by the in vivo
selection of gene vector-transduced cells as well as potential
bystander effects [22–25].
The results presented here suggest that Tre vectors are
promising antiviral reagents for therapies based on the genetic
modification of both peripheral T cells and hematopoietic stem
cells. Clearly, the procedure for ex vivo treatment of peripheral T
cells is comparably less complicated, and aims at a functional
cure by achieving long-term control of HIV, preferably in the
absence of HAART [7]. In contrast, the development of a
sterilizing cure that eradicates HIV-1 from an infected
organism, if achievable at all, most likely requires a highly
complex strategy, involving the autologous transplantation of
gene-modified HSC [22,25]. It is then expected that the
elimination of all HIV-infected cells may eventually depend
on reconstituting the patient’s immune functions, a process that
presumably requires additional and potentially gene therapy-
unrelated approaches such as, for example, immune activation
and/or purging strategies [51–54]. It is likely that such multi-
pronged eradication approaches will benefit from Tre-mediated
provirus excision in the patient’s immune effector cells (e.g.
CD4+ T cells).
Important safety issues related to gene therapies are generally
connected with potential cytopathic effects caused by the
respective transgene and/or the vector technology used. The
latter was addressed here by using an advanced lentiviral SIN
vector design where transgene expression was placed under the
control of a Tat-inducible promoter, limiting its expression to
HIV-infected cells. This strategy circumvents a major shortcoming
of various antiviral gene therapies, the continued expression of
foreign transgenes [23], thereby minimizing undesired transgene-
related side effects such as immunogenicity.
Obviously, expression of Tre-recombinase from a Tat-
inducible promoter presumably precludes provirus excision in
latently infected cells. It is therefore conceived that in clinical
virus eradication approaches Tat-responsive Tre-expressing
vectors will only be used in combination with purging drugs
that, as previously shown, not only specifically activate the
transcription of otherwise quiescent proviral genomes [55,56],
but, at the same time, will also enable Tat-mediated Tre
expression from the vector used in the present study. In this
context it is also important to note that a recent study
demonstrated that drug-induced purging alone does not result
in the elimination of patient-derived infected resting CD4+ T
cells, even when autologous CTLs were present [57]. In fact,
after virus reactivation these cells where only killed when the
HIV-specific CTLs were pre-stimulated, suggesting that virus
eradication depends at least on a combination of purging drugs
with therapeutic vaccination strategies [57]. It is expected that
such an approach would further benefit from the inclusion of an
additional anti-HIV gene therapy [25,58], such as Tre-mediated
provirus excision [22]. It is also noted that recent computational
modeling of HIV dynamics in the presence of a replication
incompetent Tre-recombinase-expressing therapeutic vector
Figure 3. Analysis of potential Tre-related cytopathic effects. Exponentially growing Jurkat T cells were transduced with LV-cCtr, or LV-cTre
encoding constitutively expressed Tre-recombinase, or mock transduced. After enriching GFP+ cells by FACS (LV-cCtr or LV-cTre), cells were cultured
for up to 15 weeks. Every week cells were harvested and analyzed. (A) Western blot analysis of the indicated proteins using rabbit polyclonal anti-Tre
serum and mouse anti-a-Tubulin antibodies. Protein signals were visualized using an Odyssey Infrared Imaging System (LI-COR). (B) Metabolic activity
measured by MTT assay; (C) Apoptosis assessed by Annexin V assay at week 15 of constitutive Tre expression; (D) Cell cycle progression monitored by
DNA staining at week 15 of constitutive Tre expression. (E) Functionality of human primary transduced CD4+ T cells tested by flow cytometric analysis
of CD154 and IFNc expression after PMA/ionomycin stimulation. (F) Secretion pattern of Th1-, Th2- and Th17-specific cytokines in primary transduced
CD4+ T cells after PMA/ionomycin stimulation as determined by multiplex ELISA. The pattern matches that of non-transduced cells (mock). (G) IFNc-
and IL4-specific Elispot analysis of human primary transduced CD4+ T cells after PMA/ionomycin stimulation. (H) CD34+ HSC were transduced with LV-
Tre (Tat inducible promoter configuration) and 100 cells were seeded into cytokine-containing methyl-cellulose. Culture dishes were incubated for 14
days at adequate conditions, before counting colonies. (I) HSC differentiation assay as in panel F using an LV constitutively expressing Tre-
recombinase (LV-cTre).
doi:10.1371/journal.ppat.1003587.g003
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suggested that such an approach may indeed clear all HIV from
the system in the long term [59].
Clearly, our study does not investigate the efficacy of Tre for
latent proviruses. This is a significant limitation that will be
addressed in the future. Particularly, it will be of interest to see
whether a residual Tat level exists in latently infected cells that
enables Tre expression by the current vector design. Alterna-
tively, Tat-independent vectors that employ drug-inducible
promoters may permit conditional Tre expression in resting
cells. For example, advanced doxycycline-responsive promoter
systems hold the promise to further increase biosafety of gene
therapies by actively controlling transgene expression [60]. In
this context one may also conceive the direct delivery of Tre-
recombinase into patients, for example by applying Tre-
containing virus like particles [61]. It is noted, that excision of
proviral DNA by recombinant cell permeable Tre-recombinase
has been already demonstrated in cell cultures [34]. Thus, such
advanced Tre delivery systems are conceived to play an
important role in the future, particularly for targeting latently
infected resting cells.
Another safety aspect that should not be underestimated is
based on Tre’s pronounced target site specificity. The fact that the
site-specific recombination process mediated by such Cre-derived
enzymes neither produces free DNA ends (e.g. double-strand
breaks) nor requires additional host factors [62], minimizes the
oncogenic risk. In agreement, the advanced molecular cytogenetic
analyses presented here demonstrate the absence of Tre-related
genome-wide off-target effects. This distinguishes Tre-recombi-
nase from CCR5-specific ZFNs, which may suffer from off-target
cleavage specificities [49,63,64]. Nevertheless, virus entry inhibi-
tion by CCR5 knockout represents a highly attractive antiviral
strategy that may be exploited to its full extent when combined
with Tre-recombinase technology, thereby not only blocking de
novo infection but also targeting already infected cells for provirus
excision.
The presented data suggest that antiviral gene therapies are
feasible using conditionally expressed, engineered Tre-recombi-
nases that precisely remove HIV-1 proviral DNA without
cytopathic effects. Antiviral in vivo activity was observed by
transduction of both CD4+ T cells and CD34+ HSC. Particularly
the latter stem cell-based approach may be a valuable component
of future eradication strategies to cure HIV [22,25]. The fact that
the current Tre-recombinase recognizes particularly HIV-1
subtype A isolates may limit its broad application. However, the
recent identification of highly conserved HIV-1 LTR sequences
[65] in combination with a novel loxLTR search tool [35] now
permits the engineering of advanced Tre-recombinases with
activity against the majority of HIV-1 variants.
Clearly, it is not expected that HIV-1 can be eradicated by Tre
activity alone. As outlined above, future HIV eradication strategies
are conceived to be a combination of various antiviral approaches
(e.g. drug-based and gene therapies), host immunity enhancing
treatments (e.g. therapeutic vaccination approaches), and purging
attempts to overcome latency [51–53]. In summary, our data
support the notion that Tre-recombinase technology can be a
valuable component of such a multi-tiered strategy to treat HIV-
infected patients.
Materials and Methods
Ethics statement
The animal experiments were performed according to the
guidelines of the German Animal Protection Law. The experi-
mental protocols were reviewed and approved by the relevant
German authority, the local ethics commission (A¨rztekammer
Hamburg; OB-050/07 and WF-010/2011) and the Freie und
Hansestadt Hamburg, Beho¨rde fu¨r Gesundheit und Verbrau-
cherschutz (Nr.: 63/09 and 23/11).
Generation of lentiviral vectors and proviral constructs
The lentiviral (HIV-1-based) SIN vector backbone has been
described previously [28,66]. Briefly, the vector comprises self-
inactivating long terminal repeats (SIN LTRs) (DU3, R, U5), splice
donor (SD), splice acceptor (SA), packaging signal (Y), central
polypurine tract (cPPT), and the Rev response element (RRE). A
post-regulatory element derived from woodchuck hepatitis virus
(PRE) ensures efficient posttranscriptional RNA processing [67,68]
and a duplicated simian virus 40 (SV40) upstream polyadenylation
enhancer element (USE) optimizes termination of transgene
transcription [28].
The transgene expression cassette includes either the open
reading frame of Tre-recombinase (tre) [18] or a scrambled
version, plus sequences encoding the enhanced green fluorescent
protein (egfp) [28]. The scrambled version serves as a negative
control (Ctr); since all ATG start codons were replaced by TGA
stop codons, and all GTG triplets by CCT, the respective mRNA
cannot be translated into a protein. The tre and scrambled
sequence are under the control of a Tre-resistant variant of the
HIV-1 NL4-3 LTR (GenBank accession number M19921),
containing one or two TAR elements. The TAR duplication
(2TAR) was generated by standard PCR technology using HIV-1
NL4-3 proviral DNA as the template for amplification. Expression
of egfp is under the control of the constitutive human phospho-
glycerate kinase (PGK) promoter [27], resulting in a dual-
promoter vector design.
The proviral construct pNLT2DenvBLB was generated by
replacing the BlpI6XhoI fragment of construct pNLT2DenvPuro
[18] with the coding sequence for a fusion protein (BLB) composed
of mTag-BFP (Evrogen) and blasticidin-S deaminase [69], both
linked by the linker sequence 59-
GCGCTAGGTGCTGCCGCCGGTGGT-39.
The proviral plasmid pNLT2env(BaL)mCherry, encoding
CCR5-tropic replication-competent HIV-1 was constructed by
inserting the env gene (2572 bp) derived from plasmid pWT/BaL
[70] (NIH AIDS Research & Reference Reagent Program,
Cat.No. 11414) into the previously described vector pNLT2Denv-
Puro [18]. Puromycin resistance encoding sequences were
replaced by the gene (711 bp) encoding the autofluorescent
protein mCherry, which was derived from the plasmid pRSET-
mCherry [71] provided by Dr. Roger Y. Tsien, University of
California San Diego.
Cell culture
HeLa and 293T cells were cultured at 37uC and 5% CO2 in
Dulbecco’s modified Eagle medium (DMEM; Biochrom) contain-
Figure 4. Analysis of potential Tre-related genotoxic effects. (A) SKY (spectral karyotyping) analysis of metaphase spreads isolated from
primary human CD4+ T cells overexpressing Tre for 21 days. An RGB display of the 24-color SKY hybridization of a representative normal metaphase is
shown. (B) Array-CGH analysis of DNA isolated from primary human CD4+ T cells overexpressing Tre compared to mock-transfected cells. A
representative chromosome (Chr17) is shown. Normal log2 ratios of color intensities (24 to +4) for each probe populate the chart. A heterozygous
deletion would be indicated by a green dot with the value ,21. A heterozygous duplication would be indicated by a red dot with a value .0.66.
doi:10.1371/journal.ppat.1003587.g004
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Figure 5. Assay of potential Tre-related off-target effects. (A) Nucleotide sequences of genomic sites and their locations in the human
genome (in brackets). Sequences are aligned to the Tre recognition site loxLTR. Nucleotides that differ from loxLTR are shown in red. (B)
Representation of the recombination assay in E. coli. and in HeLa cells, respectively. The evolution vector pEVO-Tre-target contains two directly
repeated recombinase target sites (loxLTR) or the sequences GS1, GS2, GS3, GS4, GS5, GS6, and GS7. In E. coli, Tre is expressed from the PBAD promoter
upon induction with L-arabinose. The vector also contains the regulatory gene araC, and a chloramphenicol resistance marker (Cmr). Recombination
at the target sites leads to deletion of the 700 bp intervening region. Locations of the PCR primer binding sites (F, R) for detection of recombination
are indicated. (C) Agarose gel showing the activity of Tre on loxLTR and the lack thereof for the seven genomic sites GS1 to GS7 (lanes 3–9). Upper
panel: Recombination assayed in E. Coli. BsrG I/Xba I restriction digest results in a 4.9 kb fragment for non-recombined plasmid (two triangles) and a
4.2 kb fragment for recombined product (one triangle). Recombination tests on loxLTR served as negative and positive control (lanes 1 and 2). 2,
non-induced; +, induced with 1 mg/ml L-arabinose; M, DNA marker lane. Lower panel: Recombination assayed in HeLa cells. PCR using primers F and
R that anneal to the vector DNA results in a 0.4 kb product when recombination occurs, while the non-recombined template results in a 1.1 kb PCR
product. 2, cotransfection with pIRESneo (i.e. no Tre expression); +, cotransfection with pIRESneo-Tre [18].
doi:10.1371/journal.ppat.1003587.g005
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ing 100 units/ml of penicillin and streptomycin (PenStrep;
Biochrom) and 10% fetal calf serum (FCS; Biochrom).
To generate HeLa-smurf cells, 26105 HeLa cells were infected
with pseudotyped pNLT2DenvBLB (MOI 1). Cells were sorted for
BFP-positive cells 1 and 3 weeks after infection and cultured in
DMEM supplemented with 100 units/ml of PenStrep, 10% FCS
and 5 mg/ml blasticidin (Invivogen).
Production of viral particles
HIV-1 pseudotypes and lentiviral particles for infecting cultured
cells were produced by transient cotransfection of 26106 293T
cells with the lentiviral or proviral plasmid and the respective
packaging plasmids [27] using polyethylenimine (PEI) as a
transfection reagent according to the manufacturer’s protocol
(Polysciences, Inc.). In detail, 6 mg of pNLT2DenvBLB and 1.5 mg
of pCMV-VSV-G [72] were used for transfecting the proviral
construct, or 6 mg of lentiviral vector, 1.5 mg of pRSV-Rev [27],
1.5 mg of pCMV-VSV-G [72] and 3 mg of pMDLg/pRRE [27].
At 72 hours post transfection viral supernatants were collected and
passed through 0.2 mm pore size filters to ensure removal of any
viral aggregates.
Titers of lentiviral particles and HIV-1 pseudotypes were
determined as fluorescent forming units per ml (ffu/ml). This
involved infecting 56104 293T cells with different volumes of
viral supernatant as described below. At 72 hours post
transduction cells were harvested and analyzed by flow
cytometry for GFP or BFP expression. Samples that contained
5 to 25% GFP or BFP positive cells were used to calculate viral
titers.
Replication-competent HIV-1 for infecting humanized mice
was produced essentially as before by transfecting 26106 293T
cells with 6 mg of the HIV-1 plasmid pNLT2env(BaL)mCherry. At
day 3 post transfection, virus-containing supernatants were passed
through 0.2 mm pore size filters, concentrated using a Centricon
Plus-70 device (Millipore Corp), and adjusted with RPMI culture
medium (without supplements) to 1 ng/ml of p24 antigen.
Infection and transduction of cell cultures
Cells were infected with various amounts of virus in the
presence of 1 mg/ml polybrene (Sigma-Aldrich) and spinoculated
at 3006g for 10 min at ambient temperature. After spinoculation
cells were cultivated at 37uC and 5% CO2. Medium was changed
8 h post infection.
For transduction of primary CD4+ T cells, cultures were pre-
stimulated with CD3/CD28 magnetic beads (Invitrogen) for 24 h
according to the manufacturer’s instructions. After prestimulation,
various amounts of virus were added in the presence of 2 mg/ml
polybrene (Sigma-Aldrich) and the cells were spinoculated as
described above. After 24 h of incubation at 37uC and 5% CO2,
the transduction procedure was repeated. Prior to further analyses,
transduced cells were cultured in the presence of 500 IU IL-2 for a
further 3 days at 37uC and 5% CO2.
For transduction of CD34+ HSC, cultures were prestimulated
with the cytokine cocktail StemSpan CC110 (Stem Cell Technol-
ogies) for 24 h. Virus was added to the cells, which were
maintained in StemSpan SFEM (Stem Cell Technologies)
supplemented with cytokine cocktail CC110 and the cultures
were subjected to spinoculation as described before. After 24 h of
incubation at 37uC and 5% CO2, the transduction procedure was
repeated.
Western blot analysis
Total protein was prepared and Western blot analysis was
performed as described previously [73]. Rabbit polyclonal anti-
Tre serum (Davids Biotechnologie), mouse anti-b-Tubulin (Sigma-
Aldrich), polyclonal chicken anti-GFP (Novusbio), or polyclonal
rabbit anti-GAPDH (FL-335; Santa Cruz) antibodies were used.
Protein signals were quantified using an Odyssey Infrared Imaging
System (LI-COR).
Preparation and quantification of RNA
Total cellular RNA was prepared, reverse transcribed into
cDNA and quantified by quantitative PCR as described previously
[74].
To quantify glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) sequences the following primers were used: forward,
59-GTCATCA ATGGAAATCCCATCA-39; reverse, 59-TGG-
TTCACACCCATGACGAA-39; probe, 59-(FAM)-TCTTCC-
AGGAGCGAGATCCCTC-(TAMRA)-39.
Tre functionality assay
24 hours before transduction, the HeLa-smurf cells’ medium
was changed to medium without blasticidin. Subsequently, 26105
HeLa-smurf cells were infected with VSV-G pseudotyped LV-Tre
or LV-Ctr (MOI 7.5) as described above.
From infected cultures genomic DNA, protein, and RNA were
prepared at different time points (24–336 h) after transduction and
analyzed for genomic gag-levels, Tre expression, GFP expression,
occurrence of the circular recombination product, and the
genomic scar, as described above and below.
In addition, expression of BFP and GFP was monitored by
FACS analysis using a FACSCanto II (Becton Dickinson) system
equipped with 405, 488 and 635 nm lasers.
PCR analysis of recombination in HeLa-smurf cells
Genomic DNA was isolated from eukaryotic cells using the
QIAamp DNA Blood Mini Kit (QIAGEN GmbH). The circular
recombination product generated by Tre-mediated recombination
was detected as follows: 1 mg of genomic DNA was analyzed by
PCR using 59 Mastermix (5 Prime) with forward primer P2 (59-
GCTGCCCTCTGGTTATGTGTG-39), binding in the blb
sequence, and reverse primer P1 (59-CTTAATACC-
GACGCTCTCGCAC-39), binding in the gag sequence of
pNLT2DenvBLB (PCR conditions: 1 cycle: 94uC for 2 min/
56uC for 2 min/72uC for 2 min – 40 cycles: 94uC for 2 min/58uC
for 1.5 min/72uC for 2 min - 1 cycle: 72uC for 10 min).
To detect the genomic scar, proviral integration sites were
determined by HiLo-PCR [30]. In addition to the original
protocol, a ‘‘nested’’ HiLo-PCR was performed with an aliquot
of the first HiLo reaction to improve the yield of specific
integration site fragments. The reaction conditions for the first
and nested HiLo PCRs were as follows (50 ml total volume):
25 ml of Maxima Hot Start Green PCR Master Mix (26)
(Fermentas), and 1 pmol of HiLo primer or nested HiLo primer.
HiLo PCR was carried out with 1 mg of genomic DNA from cell
lines at the following conditions: 1 cycle: 95uC for 5 min – 25
Figure 6. Suppression of plasma viremia in mice engrafted with Tre-modified human CD4+ T cells. Rag22/2cc2/2 mice were infected
with HIV-1 after adoptive transfer of LV-Tre (T1–T11) or LV-Ctr (negative control)-transduced (T12–T18) unselected CD4+ T cell pools. Plasma viral load
(red lines) of individual mice was determined at the indicated time points after infection (p.i., post infection). Percent of human CD45+CD4+ cells in
the peripheral blood of the individual animal is indicated (blue lines).
doi:10.1371/journal.ppat.1003587.g006
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cycles: 94uC for 1 min/65uC for 1 min/72uC for 3 min - 25
cycles: 94uC for 30 sec/37uC for 30 sec/72uC for 2 min – 1
cycle: 72uC for 5 min.
The nested HiLo PCR was carried out with 0.1 ml of the HiLo
reaction under the following conditions: 1 cycle: 95uC for 5 min -
25 cycles: 94uC for 30 sec/65uC for 30 sec/72uC for 3 min - 15
cycles: 94uC for 20 sec/37uC for 30 sec/72uC for 2 min – 1 cycle:
72uC for 5 min. HiLo primers used in this study were: 59-
GAAATGCTAGGC GGCTGTCAAACCTCCACTCTA-39 to
amplify fragments upstream the HIV 59-LTR, and 59-TA-
GAGTGGAGGTTTGACAGCCGCCTAGCATTTC-39 for
fragments downstream of the HIV 39-LTR. For the nested HiLo
PCR the following primers were used: 59-AGCACCATC-
CAAAGGTCAGT-39 to amplify fragments upstream the HIV
59-LTR, and 59-AAGTAGTGTGTGCCCGTCTGTTG-39 to
amplify junction fragments downstream of the HIV 39-LTR.
Recombination efficiency assay using non-restrictive
linear amplification-mediated PCR (nrLAM-PCR)
To enrich the number of genomic DNA/LTR junctions and
proviral genome/LTR junctions, nrLAM-PCR was performed as
described previously [31]. Briefly, 0.5 mg of genomic DNA was
used as a template for linear amplification using 59-biotinylated
LTR-specific primer LTRI (59-GATATCTGACCCCTG-
GCCCTG-39). Biotinylated linear PCR products were immobi-
lized on streptavidine-conjugated magnetic beads (Dynal-Invitro-
gen). Afterwards, a 59-phosphorylated and 39-modified (dideoxy-
cytidine, ddC) linker-cassette ssDNAlinker (59-CCTA-
ACTGCTGTGCCACTGAATTCAGATCTCCCG GGTC-39)
was ligated to the 39-end of the linear amplification product.
Subsequently, the linear amplification product was amplified using
two sets of nested primers. The first round of exponential
amplification used 59-biotinylated primer LTRII (59-
GTGTGTAGTTCTGCCAATC-39) and primer LCI (59-
GACCCGGGAGATCTGAATTC-39). Biotinylated double-
stranded PCR products were immobilized on streptavidine-
conjugated magnetic beads as before, and non-biotinylated
complementary strands were eluted as substrate for further
reaction. The second round of amplification was performed with
primer LTRIII (59-AGGGAAGTAGCCTTGTGTGTG-39) and
primer LCII (59-GATCTGAATTCAGTGGCACAG-39).
nrLAM-PCR products were then used as a template for
quantitative PCR to determine the number of provirus/LTR
and Chr11q13/LTR junctions. For quantification, SYBR green
fluorescence was measured using the following sets of primers: 59-
CATGGAGCAATCACAAGTAGC-39 and 59-GTGGCTAA-
GATCTA CAGCTG-39 (provirus/LTR junction); 59-TTTAG-
TAGAGACAGGGTTTCACCATG-39 and 59-AGGGAAG-
TAGCCTTGTGTGTG-39 (Chr11q13/LTR junction).
Semi-quantitative analysis was performed with the same set of
primers under the following PCR conditions: 1 cycle: 98uC for
1 min – 19 cycles: 98uC for 10 sec/58uC for 30 sec/72uC for
45 sec - 1 cycle: 72uC for 5 min using Phusion Polymerase
(Fermentas).
High throughput sequencing
High throughput sequencing and data analysis were carried out
as described previously [31]. Briefly, nrLAM-PCR products were
amplified with bar-coded PCR primers fused to GS FLX-specific
adaptors (for primer sequences see Table S1 in Text S1), pooled
and subjected to pyrosequencing on a GS FLX sequencer (Roche),
using adaptor primer A. Sequencing reads were sorted according
to their multiple sequence identifier (MID) tags and quality filtered
to eliminate all reads that did not match long terminal repeat
(LTR) sequences at their 59-end. We identified all reads that
extended at least 20 nucleotides [31] beyond the LTR, and after
trimming LTR sequences, matched the flanking sequences to both
the human genome and pNLT2DenvBLB. We noted the number
of reads that mapped to integration sites or the blb-encoding
sequences of pNLT2DenvBLB to generate the data shown in
Table 1. The BLAT alignment tool, described in [31], as well as
the CLC Genomics Workbench package (CLCbio) were used to
map sequence reads, and the UCSC genome browser (http://
genome.ucsc.edu/) was used to visualize integration sites (Figure
S3–Figure S5 in Text S1).
Isolation of primary human cells
Isolation of CD4+ T cells from buffy coats was carried out using
the RoboSep negative selection human CD4+ T cell enrichment
kit in conjunction with a RoboSep automated cell separator
(StemcellTechnologies) according to the manufacturer’s instruc-
tions. Likewise, the preparation of CD34+ HSC from umbilical
cord blood was performed with the EasySep human cord blood
CD34+ selection kit (StemcellTechnologies) and the RoboSep
system.
Analysis of cellular toxicity
MTT assay was performed with 100 ml of cell suspension and
the MTT kit (Roche) according to the manufacturer’s instructions.
A VersaMax micro plate reader (Molecular Devices) was used for
colorimetric assay evaluation.
Analysis of apoptotic events was performed using the Annexin V
FITC kit (Invitrogen) together with the antibody Annexin V-APC
conjugate (Becton Dickinson). For analysis, 56105 cells were
harvested, stained according to the manufacturer’s protocol, and
analyzed using a BD FACSCanto II (Becton Dickinson) system.
To determine cell cycle distribution 16106 cells were harvested,
washed with PBS, suspended in 500 ml PBS/1% EDTA and fixed
drop-wise with 5 ml of 80% ice cold ethanol. After incubating for
20 min on ice, the cells were incubated for 24 h at 220uC.
Afterwards, the cells were pelleted and rehydrated in 450 ml of
PBS supplemented with 16.6 ml RNAse A (10 mg/ml; Sigma-
Aldrich) and 33 ml propidium iodide solution (0.5 mg/ml; Sigma-
Aldrich). Incubation at 37uC for 30 min, was followed by further
incubation at ambient temperature in the dark for 2 h prior to
flow cytometry using a BD FACSCanto II system.
Immune activation analysis of transduced CD4+ T cells
Primary human CD4+ T cells were stimulated for 12–24 h with
phorbol myristate acetate (PMA) (50 ng/ml final conc.) and
Figure 7. Analysis of the HIV-1 infected mice engrafted with LV-transduced (LV-Tre or LV-Ctr) unselected human CD4+ T cell pools.
(A) Plasma viral load of individual mice at the indicated time points after infection is shown. The fold difference of change in baseline levels of HIV-1
RNA copies (set to 100%) in the mean (horizontal bars; paired two-tailed t-test), and the total number of animals analyzed in each cohort are
indicated. (B) Flow cytometric detection of human CD45+CD4+ cells. (C) Lentiviral vector-derived GFP expressing human CD4+ cells in the peripheral
blood of the animals (indicated in percent). (D) Immunohistochemical analysis of spleen sections prepared from mice engrafted with either LV-Tre
(left panels) or LV-Ctr (right panels) transduced T cells and stained for human CD3 and HIV p24 antigen. Scale bars indicate 100 mm.
doi:10.1371/journal.ppat.1003587.g007
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ionomycin (0.67 mM final conc.). Specific cytokine levels were
monitored by ELISA, Elispot and intracellular cytokine staining
(ICS).
Human Th1, Th2, Th17 Cytokine Multi-Analyte ELISArray
(Qiagen) was performed with supernatants from 16106 stimulated
cells or unstimulated controls, according to the manufacturer’s
instructions. ICS was essentially performed as previously described
[75] with the modification that monensin (Biolegend) was used to
inhibit secretion. Mouse anti-human CD3-APC H7 (BD Biosci-
ences), mouse anti-human CD4-APC (Becton Dickinson) and
mouse anti-human CD154-PE (BD Pharmingen) antibodies were
used for surface staining according to the manufacturer’s
instructions, except that a 4-fold excess of the CD154 antibody
was directly added to the cells during stimulation. For intracellular
staining, mouse anti-human IFNc-PE-Cy7 antibody (BD Phar-
mingen) was used. Live/dead staining was performed in parallel
using the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for
405 nm excitation (Life Technologies).
Elispot analysis was essentially performed as previously
described [76]. Briefly, polyvinylidene plates (96-well; Millipore)
were coated with 50 ng of recombinant anti-human IFNc
antibody (Mabtech), or 50 ng of recombinant anti-human IL4
antibody (Mabtech) in phosphate-buffered saline at 4uC for 12 h.
Afterwards, 36103 to 16105 cells were seeded on the coated plates
and stimulated with PMA/ionomycin as indicated above. Secreted
IL4 or IFNc was detected using the biotinylated detection
antibodies anti-human IL4 (Mabtech) or anti-human IFNc
(Mabtech).
Colony forming unit (CFU) assays
The differentiation potential of transduced HSC cells was
performed with methocult H4435-enriched methylcellulose (Stem
Cell Technologies) according to manufacturer’s protocol. For this,
100 transduced or mock treated cells were suspended in 1 ml of
methylcellulose and seeded into a 3.5 cm diameter cell culture dish
(Stemcell Technologies). After incubation at 37uC and 5% CO2
for 14 days, various cell colonies were identified and counted.
Spectral karyotyping (SKY) assay
Tre overexpressing primary human CD4+ T cells were arrested
in mitosis 21 days post transduction by treating the cells with
0.1 mg/ml colcemid for 4 hours. Cells were then treated with
75 mM KCl, incubated at 37uC for 15 min and fixed in 75%
methanol/25% acetic acid. Cell suspension was dropped onto
glass slides. Metaphase chromosomes were hybridized with the
SKY probe mixture and analysed as previously described [77]
using the SpectraCube system (Applied Spectral Imaging) coupled
to an epifluorescence microscope (Leica).
Array-comparative genomic hybridization (array-CGH)
analysis
Lentiviral transduced Tre expressing primary human CD4+ T
cells were harvested 21 days post transduction and genomic DNA
was extracted using the QIAamp DNA Blood Mini kit (Qiagen) for
array-CGH analysis. DNA was hybridized against DNA from
mock-transfected cells on an Agilent SurePrint G3 Human CGH
Microarray Kit 26400K. The minimum number of probes
affected to designate an aberration was set to 3. The median over
all probe spacing was 5.3 kb (4.6 kb in RefSeq genes) on the array
used.
Off-target recombination analysis
Potential off-target Tre recombination sites were identified by
screening the human genome using the bioinformatics tool,
SeLOX [35]. The respective genomic sites were cloned into the
recombination reporter plasmid pEVO-Tre-target [18]. In E. coli,
recombinase expression was induced with L-arabinose (Sigma-
Aldrich) at 1 mg/ml. Plasmid DNA was isolated from overnight
cultures and digested with BsrGI and XbaI (NEB), resulting in
different fragment sizes for recombined versus non-recombined
substrate on agarose gels. Recombination on the Tre target
loxLTR served as positive control. In eukaryotic cell culture, HeLa
cells were cotransfected with the reporter plasmids and the
expression plasmid pIRESneo-Tre [18]. DNA was isolated from
the cells 48 h post transfection and analyzed for recombination by
polymerase chain reaction using the primers F: 59- GACAA-
TAACCCTGATAAATGC-39, and R: 59-
CCTTAAACGCCTGGTGCTAC-39.
Generation of humanized Rag22/2cc2/2 (hu-Rag2) mice
Humanized Balb/c Rag22/2cc2/2 (provided by M. Ito,
Central Institute for Experimental Animals, Kawasaki, Japan)
were bred and maintained under specific pathogen-free conditions
using individually ventilated cages (IVC).
To generate human T cell transplanted Rag22/2cc2/2 mice, 6
week old animals were preconditioned by intra-peritoneal (i.p.)
injection of 100 ml of clodronate liposomes (obtained from Dr. N.
van Rooijen, Department of Molecular Cell Biology, Amsterdam,
Netherlands). Twenty four hours later, animals were irradiated
using a dose of 262 Gy (6 h and 2 h before transplantation) from a
Cesium 137 source at 3.75 Gy/min (CSL-12; Conservatome).
Subsequently, mice were transplanted with 36106 lentiviral vector
(LV-Tre or LV-Ctr) transduced human CD4+ T cells in 150 ml
PBS containing 0.1% human AB serum (PAN Biotech GmbH) by
i.p. injection. Analysis of human cell engraftment was verified by
FACS analysis of peripheral blood samples at 8 to 10 weeks post
transplantation, using retro-orbital sampling. Likewise, following
HIV-1 infection blood samples were analyzed every second to
fourth week for a period of 4 months.
Animals transplanted with human hematopoietic stem/progen-
itor cells (CD34+ HSC) were generated by injecting newborn
Rag22/2cc2/2 mice 24 h after birth intra-hepatically (i.h.) with
36105 lentiviral vector (LV-Tre or LV-Ctr) transduced CD34+
cells in 30 ml PBS containing 0.1% human AB serum. Prior to i.h.
injection, the newborns were irradiated with 262 Gy as before.
Engraftment was verified by FACS analysis of peripheral blood
samples at 10 to 12 weeks post transplantation and, following
HIV-1 infection, every second to third week for a period of 3
months.
HIV-1 infection of humanized mice
CD4+ T cell or CD34+ HSC transplanted mice were infected by
i.p. injection of 100 ng p24 antigen (108 HIV-1 RNA copies) of
CCR5-tropic HIV-1 pNLT2env(BaL)mcherry, containing
Figure 8. Tre-mediated antiviral effects in Rag22/2cc2/2 mice engrafted with Tre-transduced human CD34+ HSC. Animals engrafted
with LV-Tre (HSC1-HSC10) or LV-Ctr (negative control)-transduced (HSC11–HSC18) unselected cord blood-derived CD34+ HSC pools were infected
with HIV-1 and analyzed over time. Plasma viral load (red lines) of individual mice was determined at the indicated time points after infection (p.i.,
post infection). Percent of human CD45+CD4+ cells in the peripheral blood of the individual animal is indicated (blue lines).
doi:10.1371/journal.ppat.1003587.g008
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Figure 9. Suppression of plasma viremia in the Rag22/2cc2/2 mice engrafted with Tre-modified (LV-Tre) CD34+ HSC. (A) Plasma
viremia was determined at the indicated time points after infection of LV-Tre or LV-Ctr (negative control) transduced animals. The fold difference of
change in baseline levels of HIV-1 RNA copies (set to 100%) in the mean (horizontal bars; paired two-tailed t-test), and the total number of animals
analyzed in each cohort are indicated. (B) Human CD45+CD4+ cells and, (C) Transgenic GFP expressing human CD4+ cells in the peripheral blood of
the animals (indicated in percent) were detected by flow cytometric analysis. (D) Immunohistochemical analysis of lymph node sections prepared
from mice engrafted with either LV-Tre (left panels) or LV-Ctr (right panels) transduced HSC and stained for human CD3 and HIV p24 antigen. Scale
bars indicate 50 mm.
doi:10.1371/journal.ppat.1003587.g009
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loxLTR Tre-recombinase target sites. Animals were bled from the
retro-orbital venous sinus two weeks post infection, followed by
collection of blood every second, third or fourth week. Viremia
was assayed by diluting cell-free mouse plasma with human serum
(PAN Biotech GmbH) using the ultrasensitive (,20 HIV-1 RNA
copies/ml) Cobas AmpliPrep/Cobas TaqMan HIV-1 Test version
2.0 (Hoffmann-La Roche Ltd.).
Analysis of human cells in mouse tissues
For analysis of peripheral cells, 50 ml to 100 ml of blood was
collected from the retro-orbital venous sinus (r.o.) into 100 ml
bleeding-buffer (PBS plus 10 mM EDTA) and red blood cells were
lysed by treatment with Red Blood Cell Lysing Buffer (Sigma-
Aldrich). The white blood cell pellet was resuspended in FACS-
buffer (PBS containing 2% FCS and 2 mM EDTA) and stained
with monoclonal antibodies.
Single cell suspensions of various organs (thymus, spleen, liver
and bone marrow) for antibody staining and FACS analysis were
prepared at necropsy by manual tissue dissection and filtering
through a sterile 70 mm nylon mesh (BD Biosciences).
Stained cells were analyzed in FACS-buffer plus 1% parafor-
maldehyd using a FACSCanto II (Becton Dickinson) system with
BD FACSDiva Software v5.0.3 and FlowJo software v7/9 for PC
(Treestar). To monitor human cell engraftment, r.o. collected cells
were stained with monoclonal antibodies raised against mouse
CD45.2 (104) and human CD45 (H130), human CD3 (UCHT1),
and human CD19 (HIB19) (all from eBioscience Inc.). The
transduction rate was monitored by vector-derived GFP expres-
sion. HIV-1 infected mice were analyzed by staining with
monoclonal antibodies directed against the human antigens
CD45 (H130), CD4 (RPA-T4) (both from eBioscience Inc.),
CD3 (UCHT1), CD8 (B9.11) (both from Beckman Coulter Inc.),
CCR5 (3A9) and CXCR4 (12G5) (both from BD Pharmingen).
Isotype antibodies and cells obtained from non-transplanted mice
served as negative staining controls.
Immunohistochemical analysis
Formalin fixed and wax embedded sections were analyzed.
Deparaffinized sections were incubated in citrate buffer in an 85uC
waterbath overnight for human CD3 antigen detection. Mono-
clonal anti-human CD3 (Dako M7254, clone F7.2.38) was used in
a 1:1000 dilution. Biotinylated anti-mouse monoclonal antibody in
combination with horseradish peroxidase streptavidin was used for
visualisation. The TNB-Amplification Kit (Dako) and diamino-
benzidine were used as substrates. Sections were counterstained
with haemalumn.
To visualize p24 antigen, the monoclonal antibody clone Kal-1
(Dako) was used. Deparaffinized sections were boiled for 20 min in
retrieval buffer S 1699 (Dako) using a pressure cooker set at
100uC. Streptavidin alkaline phosphatase and the TNB-Amplifi-
cation Kit with Permanent Red were used for visualisation.
For staining mesenteric lymph nodes, detected in HSC
transplanted Rag22/2cc2/2 mice, sections were incubated in
titrated concentrations of mouse monoclonal anti-HIV p24 (Kal-1;
Dako) and anti-human CD3 (SP7; Thermo Scientific) antibodies
using an automated Ventana Discovery Module (Ventana Medical
Systems). Stainings were developed according to the manufactur-
er’s protocol as described previously [38].
Statistical analysis
Significant values between the initial analysis (at week 2 post
HIV-1 infection) and the final analysis (at week 12 or 16 post HIV-
1 infection) within the LV-Tre animal group and the LV-Ctr
animal group were calculated using the Student’s paired two-tailed
t-test of the GraphPad Prism Program version 5.03 (GraphPad
Software). The two-tailed p values less than 0.05 were considered
significant.
Supporting Information
Text S1 Text S1 describes the method analyzing the activity of
Tre against LTR sites of different HIV-1 strains and provides
supporting figures demonstrating the Tat responsiveness of LV
constructs, data plots of Tre analysis in HeLa-smurf cells, mapping
of HIV integrations sites in HeLa-smurf cells, cellular growth
curves upon Tre expression, detailed array-CGH analysis of the
human chromosomes, Tre activity testing on different HIV-1
isolates, analysis of HIV-1 coreceptor expression in LV-transduced
CD4+ T cells, and FACS analyses of single cell suspensions derived
from various organs of Tre-transduced and HIV-infected mice.
Finally, the sequences of bar-coded fusion primers used for
pyrosequencing are provided.
(PDF)
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